A comparative study of Silodosin vs. Tamsulosin in the management of Benign Prostatic Hyperplasia: Outcomes in a tertiary care setting in Karachi
Abstract
Background: Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) are prevalent among aging males, with acute urinary retention (AUR) being a common urological emergency. Alpha-blockers, such as tamsulosin and silodosin, are widely used in managing BPH-related LUTS and improving outcomes in Trial Without Catheter (TWOC). However, the comparative efficacy of these two medications remains a topic of clinical interest. This study aims to compare the efficacy of tamsulosin versus silodosin in achieving successful TWOC and improving the International Prostate Symptom Score (IPSS) in patients with BPH at a tertiary care hospital in Karachi.
Methodology: A randomized controlled trial was conducted involving 100 male patients with BPH, aged 45-85 years, who were randomly assigned to two groups: Group A (silodosin, 50 patients) and Group B (tamsulosin, 50 patients). The primary outcomes included successful TWOC (defined as a post-void residual volume of <100 ml) and improvement in IPSS after one month. Statistical analyses were performed using the chi-square and Mann-Whitney U tests, with a significance level set at P ≤ 0.05.
Results: In Group A, 70% of patients achieved a successful TWOC, compared to only 20% in Group B (P = 0.001). The mean IPSS score in Group A was significantly lower than in Group B (P = 0.001), indicating better symptom control with silodosin.
Conclusion: Silodosin demonstrated superior efficacy in facilitating TWOC success and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 100 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.